Practice
Featured experience
Amazon.com $15 billion notes offering
We advised the underwriters on the offering
Circle $1.05 billion IPO
We are advising Circle on its IPO, the first IPO by a stablecoin issuer
Novartis $6 billion notes offering
We advised Novartis on the investment-grade debt offering
SailPoint $1.4 billion IPO
The shares are listed on the Nasdaq Global Select Market
Trepont Acquisition Corp. I $232 million IPO
Davis Polk advised Trepont Acquisition Corp I on its $232 million initial public offering of 23,000,000 units. Each unit had…
Shui On Land $200 million high-yield notes reopening
Davis Polk advised the sole lead manager in connection with a $200 million Regulation S green bonds offering of 5.75% senior…
Banco Santander $1.5 billion offering of Tier 2 subordinated notes
Davis Polk advised Banco Santander, S.A. in connection with its SEC-registered offering of $1.5 billion aggregate principal…
NextEra Energy Partners $600 million convertible senior notes offering
Davis Polk acted as special product counsel to the initial purchaser in connection with a Rule 144A offering by NextEra…
Banco Santander renovation of its $15 billion U.S. commercial paper program
Davis Polk advised Banco Santander S.A. in connection with the renovation of its $15 billion U.S. commercial paper program…
BRP Group acquisition of Armfield, Harrison & Thomas
Davis Polk advised BRP Group, Inc. on its acquisition of all of the outstanding equity interests of Armfield, Harrison &…
Hilton $1.9 billion senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with the offering by Hilton Domestic…
CSX acquisition of Pan Am Railways in New England
Davis Polk is advising CSX Corp. on its acquisition of New England’s Pan Am Railways, Inc., whose rail carrier subsidiaries…
RAPT Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its…
Revance Therapeutics $125 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Revance Therapeutics, Inc. of its…